KWM
VRTX icon

Kingsview Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Kingsview Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$230K Sell
464
-81
-15% -$35.9K ﹤0.01% 1298
2026
Q1 		$243K Sell
545
-29
-5% -$13.5K ﹤0.01% 1170
2025
Q4 		$260K Buy
574
+13
+2% +$5.6K ﹤0.01% 1065
2025
Q3 		$220K Buy
561
+62
+12% +$25.9K ﹤0.01% 1099
2025
Q2 		$222K Sell
499
-46
-8% -$21.2K ﹤0.01% 1066
2025
Q1 		$264K Buy
+545
New +$254K 0.01% 937
2024
Q4 		– Sell
-447
Closed -$208K – 1193
2024
Q3 		$208K Buy
+447
New +$215K ﹤0.01% 1028
2023
Q1 		– Sell
-1,376
Closed -$397K – 950
2022
Q4 		$397K Buy
+1,376
New +$419K 0.02% 580
2022
Q3 		– Sell
-2,499
Closed -$704K – 888
2022
Q2 		$704K Sell
2,499
-139
-5% -$37.2K 0.03% 456
2022
Q1 		$688K Sell
2,638
-99
-4% -$23.5K 0.03% 505
2021
Q4 		$601K Sell
2,737
-140
-5% -$27.2K 0.03% 526
2021
Q3 		$522K Sell
2,877
-35
-1% -$6.83K 0.02% 533
2021
Q2 		$589K Buy
2,912
+78
+3% +$16.3K 0.03% 517
2021
Q1 		$604K Sell
2,834
-881
-24% -$194K 0.03% 467
2020
Q4 		$878K Buy
3,715
+1,281
+53% +$294K 0.06% 308
2020
Q3 		$662K Buy
+2,434
New +$671K 0.06% 307

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Kingsview Wealth Management's VRTX Position: Q2 2026 in Review

Kingsview Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 15% in Q2 2026, selling an estimated $35.9K and leaving 464 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #1298.

Kingsview Wealth Management first reported a position in VRTX in Q3 2020 and has held it in 16 quarters since. The position peaked at $878K in Q4 2020. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Kingsview Wealth Management held 464 shares of Vertex Pharmaceuticals worth $230K as of Q2 2026.
  • Kingsview Wealth Management sold 81 Vertex Pharmaceuticals shares in Q2 2026, an estimated $35.9K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Kingsview Wealth Management's portfolio in Q2 2026, its #1298 holding.
  • Kingsview Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 16 quarters since.
  • Kingsview Wealth Management's Vertex Pharmaceuticals position peaked at $878K in Q4 2020.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.